Article Details

EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre ...

Retrieved on: 2024-07-02 21:13:55

Tags for this article:

Click the tags to see associated articles and topics

EU CHMP issues negative opinion on Apellis MAA application for pegcetacoplan (Syfovre .... View article details on hiswai:

Summary

The article discusses the European Medicines Agency's CHMP rejecting marketing authorisation for pegcetacoplan, an AMD treatment, despite some support. Apellis Pharmaceuticals plans to seek re-examination. This links to tags on regulatory processes and drug development.

Article found on: www.optometrytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up